Stock FCM FRIULCHEM S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Friulchem S.p.A.

Equities

FCM

IT0005378457

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-07-12 am EDT 		5-day change 1st Jan Change
0.785 EUR 0.00% Intraday chart for Friulchem S.p.A. -1.88% -21.50%
Jul. 03 ITALY GROWTH WINNERS & LOSERS: Finanza.tech and Eles on a roll AN
Mar. 22 Friulchem returns to profit in 2023; increases financial debt AN

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.48 for the 2023 fiscal year.
  • The company appears to be poorly valued given its net asset value.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
FRIULCHEM S.P.A. Stock Friulchem S.p.A.
-21.50% 5.14M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
A+
NOVARTIS AG Stock Novartis AG
+17.90% 228B
B-
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
  1. Stock Market
  2. Equities
  3. FCM Stock
  4. Ratings Friulchem S.p.A.